Juno Therapeutics, Inc. (NASDAQ:JUNO) Director Richard Klausner sold 12,000 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $42.66, for a total transaction of $511,920.00. Following the completion of the sale, the director now owns 783,536 shares of the company’s stock, valued at approximately $33,425,645.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Richard Klausner also recently made the following trade(s):
- On Monday, August 7th, Richard Klausner sold 12,000 shares of Juno Therapeutics stock. The shares were sold at an average price of $30.34, for a total transaction of $364,080.00.
- On Friday, July 7th, Richard Klausner sold 24,000 shares of Juno Therapeutics stock. The shares were sold at an average price of $29.39, for a total transaction of $705,360.00.
Shares of Juno Therapeutics, Inc. (JUNO) opened at 41.85 on Monday. Juno Therapeutics, Inc. has a 52 week low of $17.52 and a 52 week high of $44.60. The firm has a 50-day moving average of $32.06 and a 200 day moving average of $26.37. The firm’s market cap is $4.39 billion.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. The business had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. Juno Therapeutics’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same period last year, the company earned ($0.64) earnings per share. Equities research analysts predict that Juno Therapeutics, Inc. will post ($3.12) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/09/11/juno-therapeutics-inc-juno-director-sells-511920-00-in-stock.html.
A number of brokerages have commented on JUNO. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a research note on Tuesday, May 23rd. Wedbush reiterated a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a research note on Tuesday, June 6th. Wells Fargo & Company reiterated an “outperform” rating and issued a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 20th. Finally, Zacks Investment Research upgraded shares of Juno Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $34.88.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company lifted its holdings in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics during the second quarter valued at about $105,000. QS Investors LLC purchased a new stake in Juno Therapeutics during the second quarter valued at about $135,000. Macquarie Group Ltd. purchased a new stake in Juno Therapeutics during the second quarter valued at about $248,000. Finally, Great West Life Assurance Co. Can lifted its holdings in Juno Therapeutics by 80.5% during the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 3,800 shares during the last quarter. 70.76% of the stock is currently owned by institutional investors and hedge funds.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.